Corrigendum to "Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review" [Pharmacol. Res. 177 (2022) 106076]
1 Centre for Natural Products in Health, Robert Gordon University, Aberdeen, UK. Electronic address: c.wainwright@rgu.ac.uk.
2 Department of Biochemistry and Immunology, Universidade Federal de Minas Gerais, Brazil.
3 Molecular & Biomedical Science, University of Adelaide, Australia.
4 Nelson Marlborough Institute of Technology, New Zealand.
5 Green Mission Pierre Fabre, Pierre Fabre Laboratories, Toulouse, France.
6 AbbVie Inc., Integrated Discovery Operations, North Chicago, USA.
7 Royal Botanic Gardens Kew, Richmond, Surrey, UK; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, UK.
8 Department of Pharmacy, School of Medicine, University of Naples Federico II, Italy.
9 Department of Pharmacy, School of Medicine, University of Naples Federico II, Italy; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
10 Department of Pharmacology, College of Graduate Studies, Midwestern University, IL, USA.
11 NIH Special Volunteer, Wayne, PA, USA.
12 Royal Botanic Gardens Kew, Richmond, Surrey, UK.
13 Laboratory of Animal Venoms and Toxins, Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
14 Spedding Research Solutions, Paris, France.
15 School of Pharmaceutical Sciences, University of Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.